Last reviewed · How we verify
Conventional paclitaxel or Taxol
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.
Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.
At a glance
| Generic name | Conventional paclitaxel or Taxol |
|---|---|
| Sponsor | Jina Pharmaceuticals Inc. |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane that binds to the β-subunit of tubulin dimers and promotes microtubule assembly while inhibiting disassembly. This leads to stabilization of the microtubule cytoskeleton, disrupting normal mitotic spindle dynamics and causing cells to arrest in the G2/M phase of the cell cycle, ultimately triggering apoptosis. It is effective against a broad range of solid tumors.
Approved indications
- Metastatic carcinoma of the ovary
- Breast cancer (metastatic and adjuvant)
- Non-small cell lung cancer
- Kaposi's sarcoma
- Various solid tumors (phase 3 pipeline)
Common side effects
- Neutropenia
- Peripheral neuropathy
- Myalgia/arthralgia
- Alopecia
- Nausea/vomiting
- Diarrhea
- Hypersensitivity reactions
- Anemia
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer (PHASE2)
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (PHASE3)
- A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (PHASE2)
- Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (PHASE1)
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional paclitaxel or Taxol CI brief — competitive landscape report
- Conventional paclitaxel or Taxol updates RSS · CI watch RSS
- Jina Pharmaceuticals Inc. portfolio CI